68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

Sponsor
Peking University First Hospital
Study ID
NCT07508852
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sequential [18F]-FDG PET/CT — DIAGNOSTIC_TEST
    Based on individual clinical circumstances, eligible patients will undergo sequential \[18F\]FDG PET/CT and \[68Ga\]Ga-PFD3 PET/CT scans within one week.
  • [68Ga]Ga-PFD3 PET/CT scan — DIAGNOSTIC_TEST
    Based on individual clinical circumstances, eligible patients will undergo sequential \[18F\]FDG PET/CT and \[68Ga\]Ga-PFD3 PET/CT scans within one week.

Study Details

This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).

Key Dates

First listed
Apr 2, 2026
Start date
Oct 22, 2025
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Eligible participants
    Sequential \[18F\]-FDG PET/CT and \[68Ga\]Ga-PFD3 PET/CT

Primary Outcome Measure

Adverse events (assessed using CTCAE grades) [ Time Frame: 1 week after injection ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies